|Description||Aminoglutethimide is an anticancer drug that belongs to the family of drugs called nonsteroidal aromatase inhibitors. Aminoglutethimide is used to decrease the production of sex hormones (estrogen in women or testosterone in men) and suppress the growth of tumors that need sex hormones to grow. Aminoglutethimide is marketed under the tradename Cytadren by Novartis around the world. It blocks the production of steroids derived from cholesterol and is clinically used in the treatment of Cushing's syndrome and metastatic breast cancer. It is also a drug of abuse by body builders.|
|Synonyms||Ainoglutethimide; Cytadren; Orimeten; dl-Aminoglutethimide; p-Aminoglutethimide; Elipten; Aminoglutetimida; Aminoglutethimidum; Ba-16038; Cytadren (TN); Prestwick_243; CCRIS 7562; CHEBI:2654; Aminoglutethimidum [INN-Latin].|
Cgp 45688 is an non-steroidal aromatase inhibitor originated byNovartis. It has anti-tumor effects, but no development for treatment of cancer was reported.
Formestane is a second generation selective aromatase inhibitor with an IC50 of 80 nM.
This active molecular has a potential antineoplastic activity. As a retinoic acid metabolism blocking agent (RAMBA), liarozole inhibits P450-dependent ATRA-4-hy...
Cgp 47645 is non-steroidal aromatase inhibitor with anti-tumor and endocrine effects. It is orally active.
LY 56110, a Pyrimidine derivative, is a novel class of nonsteroidal aromatase inhibitor. LY 56110 inhibited ethinamate-induced sleeping time in rats in vivo.
FR-901537, a naphthothiazin compound, has been found to be an aromatase inhibitor that could be used as a cytostatic antibiotic and was once studied in breast c...
ORG 30958 is a potent aromatase inhibitor in vivo. ORG 30958 proved to be devoid of antiestrogenic activity which indicates that the absence of cornification of...
YM 511 is a potent aromatase (CYP19) inhibitor (IC50 = 0.4 and 0.12 nM at rat ovary and human placenta cells, respectively) that weakly inhibits the synthesis o...